Your browser doesn't support javascript.
loading
Hepatic Arterial Infusion Chemotherapy Combined with Radiation Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombosis of the Main Trunk or Bilobar of the Portal Vein.
Kosaka, Yumi; Kimura, Tomoki; Kawaoka, Tomokazu; Ogawa, Yutaro; Amioka, Kei; Naruto, Kensuke; Yoshikawa, Yuki; Kikukawa, Chihiro; Suehiro, Yosuke; Yamaoka, Kenji; Ando, Yuwa; Uchikawa, Shinsuke; Morio, Kei; Nakahara, Takashi; Murakami, Eisuke; Takahashi, Shoichi; Tsuge, Masataka; Hiramatsu, Akira; Imamura, Michio; Chosa, Keigo; Awai, Kazuo; Nagata, Yasushi; Chayama, Kazuaki; Aikata, Hiroshi.
Afiliação
  • Kosaka Y; Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan.
  • Kimura T; Therapeutic Radiology, Institute and Graduate School of Biomedical Science, and, Hiroshima University, Hiroshima, Japan.
  • Kawaoka T; Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan.
  • Ogawa Y; Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan.
  • Amioka K; Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan.
  • Naruto K; Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan.
  • Yoshikawa Y; Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan.
  • Kikukawa C; Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan.
  • Suehiro Y; Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan.
  • Yamaoka K; Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan.
  • Ando Y; Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan.
  • Uchikawa S; Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan.
  • Morio K; Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan.
  • Nakahara T; Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan.
  • Murakami E; Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan.
  • Takahashi S; Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan.
  • Tsuge M; Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan.
  • Hiramatsu A; Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan.
  • Imamura M; Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan.
  • Chosa K; Diagnostic Radiology, and, Hiroshima University, Hiroshima, Japan.
  • Awai K; Diagnostic Radiology, and, Hiroshima University, Hiroshima, Japan.
  • Nagata Y; Therapeutic Radiology, Institute and Graduate School of Biomedical Science, and, Hiroshima University, Hiroshima, Japan.
  • Chayama K; Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan.
  • Aikata H; Research Center for Hepatology and Gastroenterology, Hiroshima University, Hiroshima, Japan.
Liver Cancer ; 10(2): 151-160, 2021 Apr.
Article em En | MEDLINE | ID: mdl-33977091
BACKGROUND: Overall survival of patients with advanced hepatocellular carcinoma (HCC) with Vp4 (tumor thrombosis of the main trunk or bilobar of the portal vein) is extremely poor. PURPOSE: The purpose of this study is to clarify the prognosis of hepatic arterial infusion chemotherapy (HAIC) combined with radiation therapy (RT) for advanced HCC with Vp4 and to analyze the factors that contribute to the prognosis. METHODS: In this retrospective cohort study, 51 HCC patients who were treated with HAIC and RT for portal vein tumor thrombosis and met the following criteria were enrolled: (i) with Vp4; (ii) Child-Pugh score of 5-7; (iii) Eastern Cooperative Oncology Group performance status of 0 or 1; (iv) no history of systemic therapy; and (v) from September 2004 to April 2019. RESULTS: Median overall survival and median progression-free survival were 12.1 and 4.2 months, respectively. Multivariate analysis showed >50% of relative tumor volume in the liver (HR, 3.027; p = 0.008) and extrahepatic spread with (HR, 3.773; p = 0.040) as significant and independent factors of OS. The total overall response rate (ORR) was 19.6%; ORR in main tumor was 13.7%; and ORR in Vp4 was 51.0%. None of the patients who received HAIC combined with RT for advanced HCC with Vp4 developed hepatic failure. This combination therapy of HAIC with RT was safe and well tolerated in all cases. CONCLUSION: Combination therapies of HAIC and RT might be good therapy for advanced HCC with Vp4.
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Prevencao_e_fatores_de_risco / Agentes_cancerigenos Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies Idioma: En Revista: Liver Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Japão
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Prevencao_e_fatores_de_risco / Agentes_cancerigenos Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies Idioma: En Revista: Liver Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Japão